The Pharmaceutical Market: Sweden

Date: January 31, 2013
Pages: 92
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P44CD516A20EN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: Sweden
OVERVIEW OF THE PHARMACEUTICAL MARKET IN SWEDEN

We remain of the opinion that Sweden's overall pharmaceutical market value will decline over the forecast period to 2016, both in local currency and US dollar terms. We base our view on patent expiration and cost containment policies , which will continue to stimulate consumption of cheaper generic medicines. Moreover, i n the short term, weak consumer confidence in Sweden may affect the growth of its non-prescription market , while - in the longer-term - we expect a drop in consumers' willingness to consume non-reimbursed medicines.

Headline Expenditure Projections

Pharmaceuticals: SEK42.84bn (US$6.60bn) in 2011 to SEK42.17bn (US$6.12bn) in 2012; -1.6% in local currency terms and -7.2% in US dollar terms. Forecasts broadly in line with previous quarter.

Healthcare: SEK327.00bn (US$50.36bn) in 2011 to SEK336.36bn (US$48.82bn) in 2012; +2.9% in local currency terms and -3.1% in US dollar terms. Forecasts broadly in line with previous quarter.

Medical devices: SEK21.04bn (US$3.24bn) in 2011 to SEK21.86bn (US$3.17bn) in 2012; +3.9% in local currency terms and -2.1% in US dollar terms. Forecasts broadly in line with previous quarter.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
BMI INDUSTRY VIEW

SWOT ANALYSIS

    Sweden Pharmaceuticals And Healthcare Industry SWOT
    Sweden Political SWOT
    Sweden Economic SWOT
    Sweden Business Environment SWOT

PHARMACEUTICALS RISK/REWARD RATINGS

    Table: Western Europe Pharmaceuticals And Healthcare Risk/Reward Ratings, Q113
    Rewards
    Risks

SWEDEN – MARKET SUMMARY

REGULATORY REGIME

    Intellectual Property Regime
    Pricing Regime
    Table: Price Decline For Off-Patent Drugs
    Reimbursement Regime

INDUSTRY TRENDS AND DEVELOPMENTS

    Epidemiology
    Non-Communicable Disease
    Communicable Disease
    Healthcare System
    Healthcare Financing
    Research And Development
    Table: Drug Development Member Companies Of SwedenBIO, 2011
    Table: Number Of Projects By Therapeutic Category, 2010-2011
    Clinical Trials Sector
    Medical Devices Sector

INDUSTRY FORECAST SCENARIO

    Overall Market Forecast
    Table: Pharmaceuticals Sales Indicators, 2008-2016
    Healthcare Market Forecast
    Table: Healthcare Expenditure Indicators, 2008-2016
    Table: Healthcare Governmental Indicators, 2008-2016
    Table: Healthcare Private Indicators, 2008-2016
    Key Indicators – Macroeconomic
    Table: Sweden – GDP Contribution To Growth
    Prescription Drug Market Forecast
    Table: Pharmaceutical Sales By Leading Product At Wholesale Prices, 2007-2010 (SEKmn)
    Table: Pharmaceutical Sales By Therapeutic Group At Wholesale Prices, 2007-2010 (SEKmn)
    Table: Inpatient Hospital Sales By Leading Pharmaceutical Group At Retail Prices, 2007-2010 (SEKmn)
    Table: Prescription Drug Sales Indicators, 2008-2016
    Patented Drug Market Forecast
      Table: Patented Drug Market Indicators, 2008-2016
      Generic Drug Market Forecast
      Table: Generic Drug Sales Indicators, 2008-2016
      OTC Medicine Market Forecast
      OTC Switches
      Table: OTC Sales By Therapeutic Group At Retail Prices, 2009-2010 (SEKmn)
      Table: Leading OTC Drugs At Retail Prices, 2009-2010 (SEK Millions)
      Table: OTC Medicine Sales, 2008-2016
      Pharmaceutical Trade Forecast
      Table: Parallel Imported Pharmaceutical Market at Wholesale Prices, 1997-2010
      Table: Exports and Imports Indicators, 2008-2016
      Medical Device Market Forecast
      Table: Medical Devices Sales Indicators, 2008-2016
      Other Healthcare Data
      Key Risks To BMI’s Forecasts

COMPETITIVE LANDSCAPE

      Pharmaceutical Industry
      Pharmaceuticals Manufacturing Sector
      Table: Pharmaceutical Production, 1995-2010 (Euros 000s)
      Table: Top Sweden-Based Pharmaceutical Companies By Market Capitalisation
      Table: Leading Pharmaceutical Companies By Sales At Wholesale Prices, 2007-2010 (SEKmn)
      Table: Pharmaceutical Sales By Leading Pharmaceutical Group At Wholesale Prices, 2007-2010 (SEKmn)
      Pharmaceuticals Industry Developments
      Pharmaceuticals Wholesaling
      Pharmaceutical Retailing
      Table: Drug Retail Establishments By Type, 2006-2010

COMPANY PROFILES

  Local Companies
      Meda
      Swedish Orphan Biovitrum (SOBI)
      Medivir

DEMOGRAPHIC OUTLOOK

      SWEDEN - Population By Age Group
      SWEDEN - Population By Age Group
      SWEDEN - Key Population Ratios
      SWEDEN - Rural And Urban Population

GLOSSARY

BMI METHODOLOGY

  How We Generate Our Pharmaceuticals Industry Forecasts
      Pharmaceuticals Risk/Reward Ratings Methodology
      Ratings Overview
      Table: Pharmaceuticals Risk/Reward Indicators
      Weighting
      Table: Weighting Of Components
      Sources
Skip to top


The Pharmaceutical Market: Jordan US$ 1,295.00 Jan, 2013 · 112 pages
The Pharmaceutical Market: Finland US$ 1,295.00 Mar, 2013
The Pharmaceutical Market: France US$ 1,295.00 Jan, 2013 · 107 pages
The Pharmaceutical Market: Germany US$ 1,295.00 Jan, 2013 · 112 pages

Ask Your Question

The Pharmaceutical Market: Sweden
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: